Remicade Powder For Solution For Injection 100Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Remicade: Powder for solution for injection (100mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

INFLIXIMAB (in FLIX i mab) is used to treat Crohn's disease and ulcerative colitis. It is also used to treat ankylosing spondylitis, psoriasis, and some forms of arthritis.

In-Depth Information

Remicade 100mg Powder for Injection

NDC: 578940030
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ankylosing Spondylitis, Rheumatoid Arthritis, Ulcerative Colitis

Sometimes used for but not FDA approved for the following conditions:
Behcet's Syndrome, Uveitis

Storage Information
Product is stable until the expiration date on the label if refrigerated (36 to 46 degrees F)
Store between 36 to 46 degrees F
Remicade 100mg Powder for Injection

Reported Side Effects for Remicade 100mg Powder for Injection

Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Severe Allergy Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Swelling Incidence:
>0.2%*
Severity: MODERATE
Onset: DELAYED
Dehydration Incidence:
>0.2%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cell Counts Incidence:
>0.2%*
Severity: MODERATE
Onset: DELAYED
Diaphoresis Incidence:
>0.2%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
>0.2%*
Severity: MILD
Onset: EARLY
Intestinal Blockage Incidence:
>0.2%*
Severity: SEVERE
Onset: DELAYED
Hemolytic Anemia Incidence:
>0.2%*
Severity: SEVERE
Onset: DELAYED
Constipation Incidence:
>0.2%*
Severity: MODERATE
Onset: DELAYED
Low Platelet Count Incidence:
>0.2%*
Severity: MODERATE
Onset: DELAYED
Enlarged Lymph Nodes Incidence:
>0.2%*
Severity: MODERATE
Onset: DELAYED
Slow Heart Beat Incidence:
>0.2%*
Severity: SEVERE
Onset: RAPID
Low Blood Pressure Incidence:
>0.2%*
Severity: MODERATE
Onset: RAPID
Fluid In Lungs Incidence:
>0.2%*
Severity: SEVERE
Onset: EARLY
Irritated Blood Vessels Incidence:
>0.2%*
Severity: MODERATE
Onset: RAPID
Anemia Incidence:
>0.2%*
Severity: MODERATE
Onset: DELAYED
Chest Pain Incidence:
>1.0%*
Severity: MODERATE
Onset: EARLY
Muscle Pain Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Serum Sickness Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
>1.0%*
Severity: MODERATE
Onset: EARLY
Chills Incidence:
>3.0%*
Severity: MILD
Onset: RAPID
Infection Incidence:
5.3-56.0%*
Severity: MILD
Onset: DELAYED
Antibody Formation Incidence:
7.0-62.0%*
Severity: MODERATE
Onset: DELAYED
Broken Bones Incidence:
7.0%*
Severity: SEVERE
Onset: DELAYED
Fever Incidence:
7.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cells Incidence:
7.0%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
7.0%*
Severity: MILD
Onset: RAPID
High Blood Pressure Incidence:
7.0%*
Severity: MODERATE
Onset: EARLY
Joint Pain Incidence:
8.0%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
9.0%*
Severity: MILD
Onset: EARLY
Flushing Incidence:
9.0%*
Severity: MILD
Onset: RAPID
Elevated Hepatic Enzymes Incidence:
>10.0%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
10.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
10.0%*
Severity: MILD
Onset: EARLY
Sore Throat Incidence:
12.0%*
Severity: MILD
Onset: DELAYED
Stomach Pain Incidence:
12.0%*
Severity: MILD
Onset: EARLY
Cough Incidence:
12.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
12.0%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
14.0%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
18.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
21.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Remicade

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.